Format

Send to

Choose Destination
J Med Chem. 2008 May 22;51(10):2879-82. doi: 10.1021/jm800043g. Epub 2008 Apr 22.

Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.

Author information

1
Amgen Inc., Cambridge, MA 02139, USA. brian.albrecht@amgen.com

Abstract

Tumorigenesis is a multistep process in which oncogenes play a key role in tumor formation, growth, and maintenance. MET was discovered as an oncogene that is activated by its ligand, hepatocyte growth factor. Deregulated signaling in the c-Met pathway has been observed in multiple tumor types. Herein we report the discovery of potent and selective triazolopyridazine small molecules that inhibit c-Met activity.

PMID:
18426196
DOI:
10.1021/jm800043g
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center